S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
OTCMKTS:GNFTF

Genfit (GNFTF) Stock Price, News & Analysis

$2.98
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$2.98
$2.98
50-Day Range
$2.98
$3.45
52-Week Range
$2.98
$3.45
Volume
N/A
Average Volume
1,225 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GNFTF stock logo

About Genfit Stock (OTCMKTS:GNFTF)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFTF Stock Price History

GNFTF Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Genfit Share Price (GNFT.PA)
Genfit reports 9M results
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Kepler Capital Sticks to Their Buy Rating for Genfit (GNFTF)
SVB Securities Remains a Buy on Genfit SA (GNFT)
Genfit Gears Up For Primary Biliary Cholangitis Trial Data
Genfit (GNFTF) Receives a Buy from Kepler Capital
GENFIT Announces 2023 Financial Calendar
A Long Wait For Genfit May Be Worth It
Genfit S.A. (GNFT)
Analyzing Genfit's Short Interest
See More Headlines
Receive GNFTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:GNFTF
CIK
N/A
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jean-Francois Mouney (Age 69)
    Co-Founder & Chairman of the Board
    Comp: $400.24k
  • Mr. M. Pascal Prigent (Age 56)
    Chief Executive Officer
    Comp: $606.58k
  • Prof. Bart Staels (Age 61)
    Co-Founder & Chairman of the Scientific Advisory Board
  • Mr. Thomas Baetz (Age 50)
    Chief Financial Officer
  • Mr. Pascal Caisey (Age 56)
    Chief Operating Officer
  • Dr. Meriam Kabbaj Ph.D. (Age 50)
    Chief Technology Officer
  • Dr. Dean W. Hum Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $771.84k
  • Mr. Jean-Christophe Marcoux (Age 46)
    Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
  • Mr. Laurent Lannoo (Age 54)
    Corporate Secretary & Director of Legal Affairs
  • Ms. Stefanie Magner J.D. (Age 43)
    Chief Compliance Officer & Executive VP of International Legal Affairs

GNFTF Stock Analysis - Frequently Asked Questions

How have GNFTF shares performed in 2024?

Genfit's stock was trading at $3.45 on January 1st, 2024. Since then, GNFTF stock has decreased by 13.6% and is now trading at $2.98.
View the best growth stocks for 2024 here
.

Are investors shorting Genfit?

Genfit saw a drop in short interest in February. As of February 15th, there was short interest totaling 42,400 shares, a drop of 69.8% from the January 31st total of 140,300 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.
View Genfit's Short Interest
.

How do I buy shares of Genfit?

Shares of GNFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNFTF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners